1 / 16

Effectiveness and Safety of an Octreotide Hydrogel Implant in Patients With Acromegaly

Effectiveness and Safety of an Octreotide Hydrogel Implant in Patients With Acromegaly. Carla Chieffo, VMD, PhD, 1 Lawrence A. Frohman, MD, 2 Harry Quandt, BS, 1 Stefanie Decker, MS, 1 Mônica R. Gadelha, MD, PhD 3

magar
Télécharger la présentation

Effectiveness and Safety of an Octreotide Hydrogel Implant in Patients With Acromegaly

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effectiveness and Safety of an Octreotide Hydrogel Implant in Patients With Acromegaly Carla Chieffo, VMD, PhD,1 Lawrence A. Frohman, MD,2 Harry Quandt, BS,1 Stefanie Decker, MS,1 Mônica R. Gadelha, MD, PhD3 1Endo Pharmaceuticals Inc., Chadds Ford, PA, USA; 2University of Illinois at Chicago, Chicago, IL, USA; 3Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil This research was funded by Endo Pharmaceuticals Inc., Chadds Ford, PA, USA. The information concerns an investigational use of a drug that has not been approved by the US Food and Drug Administration

  2. Approximately 60% of patients with acromegaly achieve biochemical control with octreotide long-acting release (OLAR)1 OLAR and lanreotide sustained release require monthlyinjections and are associated with large peak-to-trough changes in drug concentrations2 Drug-release technologies that extend the dosing interval and reduce drug-concentration fluctuations could improve compliance, symptom management, and tolerability A subcutaneous octreotide hydrogel implant (OHI) has been developed that provides constant octreotide release for 6 months Background 1Freda et al. J Clin Endocrinol Metab. 2005;90(8):4465-4473; 2Astruc et al. J Clin Pharmacol. 2005;45(7):836-844

  3. Objective To evaluate the effectiveness and safety of a subcutaneous 52-mg OHI for the treatment of acromegaly Study Design Phase II, open-label, randomized study at a single Brazilian center First study to evaluate the effectiveness and safety of OHI Acromegaly patients were randomized to receive one or two 52-mg hydrated OHI (60-mg octreotide acetate) Inserted subcutaneously in the upper arm on day 1 and removed at month 6 Visits were scheduled monthly through month 7 Objective and Study Design

  4. Inclusion/Exclusion Criteria

  5. Serum IGF-1 concentration assessed monthly using single blood samples (months 1–7) Serum GH concentration assessed monthly using Single blood samples (months 1, 3, 5, 7) 5 serial blood samples drawn every 30 minutes for 2 hours (day 1/preinsertion and months 2 and 4) OGTT at screening and month 6 GH concentration assessed 0, 30, 60, 90, and 120 minutes after OGTT Tumor size and quality of life (QoL) were assessed at screening and month 6 Safety Adverse events (AEs), physical examination, vital signs, electrocardiograms, gallbladder ultrasound, hematology, clinical chemistry, thyroid profiles, and HgbA1c Assessments

  6. Baseline Patient Characteristics • 11 patients met the screening criteria and were implanted • All patients completed 6 months of treatment

  7. Mean IGF-1 Concentration

  8. Normalization of IGF-1 • Normal age-adjusted range was achieved by 1 patient in the 1-implant group and 2 patients in the 2-implant group • ≥40% decrease in patients who did not normalize IGF-1

  9. Mean GH Concentration

  10. Suppression of GH • GH after OGTT at month 6 and mean on-treatment GH are shown

  11. Tumor Size • Reduced by 23% with 1 implant and 38% with 2 implants n=3 n=3 n=5 n=5

  12. Quality of Life • Patient ratings of effectiveness and satisfaction were high • Patient ratings of discomfort/pain and disruption of daily activities were low Scale: 0=lowest, 10=highest

  13. Safety *Mild insertion site pain the day of the implantation procedure; dipyrone was administered, and the pain resolved the next day

  14. Conclusions • 52-mg OHI provided consistent biochemical control over 6 months and reduced tumor size • OHI was a safe and effective delivery system for treating patients with acromegaly • High satisfaction and effectiveness ratings for the OHI • Phase III studies of the OHI (84 mg) are ongoing This research was funded by Endo Pharmaceuticals Inc., Chadds Ford, PA, USA The information concerns investigational use of a drug that has not been approved by the US Food and Drug Administration

  15. Author Disclosures Carla Chieffo: employee of Endo Pharmaceuticals Inc. Lawrence A. Frohman: consultant to Endo Pharmaceuticals Inc. Harry Quandt: employee of Endo Pharmaceuticals Inc. Stefanie Decker: employee of Endo Pharmaceuticals Inc. Mônica R. Gadelha: nothing to disclose Presenter: Theodore Danoff, MD, PhD, Vice President of Clinical Development, Endocrinology/Urology, Endo Pharmaceuticals Inc.

  16. At each monthly visit, suppression of IGF-1 GH (single GH and mean 2-h serial GH concentrations) After an OGTT at month 6, suppression of GH to <1.0 ng/mL Within patient, IGF-1 and GH concentration over the entire 6-month treatment period Reduction in tumor size QoL ratings of the treatment Endpoints

More Related